Remi M. Adelaiye-Ogala PhD
Remi M. Adelaiye-Ogala
PhD
Assistant Professor
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Epigenetics; Genomics and proteomics; Oncology; Preclinical Research; Transcriptomics; Translational Research
Professional Summary:
My research program is focused on investigating mechanistic determinants of therapeutic resistance in genitourinary cancers and developing optimal therapeutic strategies for durable clinical outcomes. My research group engages in basic and translational research in genitourinary cancers with emphasis on molecular regulation of signaling pathways in prostate and renal cancers and therapeutic strategies to overcome drug resistance mediated by genetic and epigenetic mechanisms. My expertise in state-of-the-art multi-omics assays, drug screens, and development/maintenance of patient-derived xenografts models to evaluate the efficacy of novel pipeline agents in 3D organoid cultures and animal models.
My team leverages information from multi-omics assays and drug screens with established human cell lines and patient-derived xenograft models to identify optimal therapeutic strategies to manage the disease better. Throughout my research trajectory, my expertise and contributions in epigenetics, genomics, and cancer biology and meticulous evaluation of novel and optimal treatment modalities in the preclinical setting have led to several impactful publications.
Three significant projects currently ongoing in my lab include (i) Targeting drivers of the androgen receptor (AR) cistrome reprogramming associated with advanced aggressive prostate cancer, (ii) Investigating posttranslational modulations and dynamics of pro-oncogenic glucocorticoid receptor activity as a compensatory hormone nuclear receptor in prostate cancers that have developed resistance to FDA-approved standard of care, and (iii) Development and characterization of patient-derived xenograft (PDX) and organoid models of prostate cancers, specifically from underrepresented populations.
My research goal is to leverage information from our preclinical studies to provide therapeutic strategies for optimal clinical outcomes. My goal as a mentor is to ensure that all mentees have the resources and an equal playing ground to thrive and achieve successful careers.
Education and Training:
- Fellowship, Postdoctoral Fellow, Center for Cancer Research, National Cancer Institute, NIH (2020)
- Graduate Research Assistant, School of Medicine, Indiana University (2017)
- PhD, Cancer Pathology, University at Buffalo, Roswell Park Cancer Institute Division (2017)
- BS, College of Liberal Arts & Sciences, State University of New York at Fredonia (2009)
Employment:
- Assistant Professor, Department of Medicine, Division of Hematology/Oncology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo (2022-present)
- Graduate Faculty Member, Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo (2022-present)
- Adjunct Research Assistant Professor, Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo (2021-present)
- Research Assistant Professor, Department of Medicine, Division of Hematology/Oncology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo (2021–2022)
- Research Technician, Health Research Inc. Roswell Park Cancer Institute (2010–2012)
Awards and Honors:
- American Association for Cancer Research (AACR), Minority in Cancer Research (MICR), Minority and Minority-Serving Institution Faculty Scholar Award (2023)
- Clinical and Translational Science Institute Pilot Award (2022)
- Invited panel speaker, Prostate Cancer Foundation Women in Science Forum: Celebration of Achievements of Women in Prostate Cancer Oncology and Research, Prostate Cancer Foundation (PCF) 22nd Annual Retreat (2021)
- Troup Award (2021)
- Clinical Translational Science Institution (CSTI) K Scholar (2021)
- Prostate Cancer Foundation Young Investigator Award (2019)
- Congressionally Directed Medical Research Programs, PCRP Early Investigator Research Award (2019)
- Scholar-in-Training Travel Award (2016)
- Cancer research day Indiana University, 2nd prize-Poster presentation award (2015)
- 1st prize-Award for outstanding postdoctoral fellow and graduate student poster presentation (2014)
Research Expertise:
- Development and characterization of patient derived xenografts models for preclinical investigation.
- Evaluating the efficacy of novel pipeline agents/compounds in 3D organoid cultures and animal models.
- Functional transcriptomics and epigenetic in prostate and kidney cancers
Research Centers:
- Center for Computational Research (CCR)
- Center of Excellence in Bioinformatics and Life Sciences
- Clinical and Translational Research Center (CTRC)
Grants and Sponsored Research:
- April 2024–May 2029
Posttranslational modifications of glucocorticoid receptor associated with drug resistance in prostate cancer
NCI/NIH
Role: Principal Investigator - September 2019–September 2023
Dynamics of Epigenetic Mechanisms in the Akt Signaling Pathway and Its Influences on Drug Response in Advanced Prostate Cancer
DOD-CDMRP-PCRP
Role: Principal Investigator - March 2022–March 2023
Hijacking Therapeutic Resistance in High-risk Localized and Advanced Prostate Cancer
University at Buffalo Clinical and Translational Science Institute (CTSI) via the NIH CTSA UL1
Role: Principal Investigator - October 2019–October 2022
Investigating Alterations in AR regulome following response to Kinase Inhibitors (19YOUN01)
Prostate Cancer Foundation
Role: Principal Investigator - August 2023
Therapeutic Targeting of Master Regulators in Non-Canonical AR Driven Advanced Lethal Prostate Cancers (R37 MERIT)
NCI/NIH
Role: Principal Investigator - March 2023
Testing novel treatment modalities in Androgen Receptor driven prostate cancers (ESSA Pharma)
ESSA Pharma
Role: Principal Investigator - June 2021
Targeting drivers of non-canonical AR cistrome associated with therapeutic resistance in advanced prostate cancer
Kaleida Health Foundation
Role: Principal Investigator
Journal Articles:
- Lynda Bennett, Praveen Kumar Jaiswal, Ryan V Harkless, Tiha M Long, Ning Gao, Brianna Vandenburg, Phillip Selman, Ishrat Durdana, Ricardo R Lastra, Donald Vander Griend, Remi Adelaiye-Ogala, Russell Z Szmulewitz, Suzanne D Conzen. (2023) Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer. Molecular Cancer Therapeutics, AACR Journal (Nov) doi:10.1158/1535-7163.MCT-22-0479
- Andrea K. Miyahira PhD, Jessica E. Hawley MD, MS, Remi Adelaiye-Ogala PhD, Jeremie Calais MD, MSc, Lucia Nappi MD, PhD, FRCPSC, Ravi Parikh MD, MPP, Tyler M. Seibert MD, PhD, Elizabeth V. Wasmuth PhD, Xiao X. Wei MD, Kenneth J. Pienta MD, Howard R. Soule PhD. (2022) Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting. The Prostate (Nov) doi:10.1002/pros.24461
- Adelaiye-Ogala R, Gryder BE, Nguyen YTM, Alilin AN, Grayson AR, Bajwa W, Jansson KH, Beshiri ML, Agarwal S, Rodriguez-Nieves JA, Capaldo B, Kelly K, VanderWeele DJ. (2020) Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor. Molecular cancer therapeutics (Jul), 19(7): 1436-1447. doi:10.1158/1535-7163.MCT-19-0936
- Elbanna M, Orillion AR, Damayanti NP, Adelaiye-Ogala R, Shen L, Miles KM, Chintala S, Ciamporcero E, Ramakrishnan S, Ku SY, Rex K, Caenepeel S, Coxon A, Pili R. (2020) Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma. Molecular cancer therapeutics (Jan), 19(1): 147-156. doi:10.1158/1535-7163.MCT-18-1202
- Orillion A, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti H, Elbanna M, Chintala S, Ciesielski M, Fontana L, Kao C, Elzey BD, Ratliff TL, Nelson DE, Smiraglia D, Abrams SI, Pili R. (2018) Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (Dec), 24(24): 6383-6395. doi:10.1158/1078-0432.CCR-18-0980
- Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman E, Wood AC, Ahmed K, Chintala VN, Adelaiye-Ogala R, Elbanna M, Orillion A, Chintala S, Kao C, Linehan WM, Yousef GM, Hollenhorst PC, Pili R. (2018) Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (Dec), 24(23): 5977-5989. doi:10.1158/1078-0432.CCR-18-0269
- Adelaiye-Ogala R, Damayanti NP, Orillion AR, Arisa S, Chintala S, Titus MA, Kao C, Pili R. (2018) Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma. Cancer research (Jun), 78(11): 2886-2896. doi:10.1158/0008-5472.CAN-17-3386
- Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R. (2017) EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer research (Dec), 77(23): 6651-6666. doi:10.1158/0008-5472.CAN-17-0899
- Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, Chintala S, Ordentlich P, Kao C, Elzey B, Gabrilovich D, Pili R. (2017) Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (Sep), 23(17): 5187-5201. doi:10.1158/1078-0432.CCR-17-0741
- Wentink MQ, Verheul HMW, Pal SK, George S, Voortman J, Danchaivijitr P, Adelaiye R, Poslinski D, Groman A, Hutson A, Pili R. (2017) Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clinical genitourinary cancer (Jul).
- Pili R, Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge MA, Wahl R, Martin JI, Miles KM, Paesante S, Adelaiye R, Godoy A, King S, Zwiebel J, Carducci MA. (2017) Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial. British journal of cancer (Mar), 116(7): 874-883. doi:10.1038/bjc.2017.33
- Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, Barrera G, Pili R. (2016) YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene (Mar), 35(12): 1541-53. doi:10.1038/onc.2015.219
- Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, Bjarnason GA, Pili R. (2015) Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Molecular cancer therapeutics (Feb), 14(2): 513-22. doi:10.1158/1535-7163.MCT-14-0208
- Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, Pili R. (2015) Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer immunology research (Feb), 3(2): 136-48. doi:10.1158/2326-6066.CIR-14-0036
- Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R. (2015) Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Molecular cancer therapeutics (Jan), 14(1): 101-10. doi:10.1158/1535-7163.MCT-14-0094
- Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, Verheul HM. (2014) Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience (Jan), 1(12): 844-53. doi:10.18632/oncoscience.106
- Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R. (2014) Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. PloS one (Jan), 9(11): e112371. doi:10.1371/journal.pone.0112371
- Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R. (2014) Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. PloS one (Jan), 9(7): e103680. doi:10.1371/journal.pone.0103680
- Fontana L, Adelaiye RM, Rastelli AL, Miles KM, Ciamporcero E, Longo VD, Nguyen H, Vessella R, Pili R. (2013) Dietary protein restriction inhibits tumor growth in human xenograft models. Oncotarget (Dec), 4(12): 2451-61. doi:10.18632/oncotarget.1586
- Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R. (2012) Development of a castrate resistant transplant tumor model of prostate cancer. The Prostate (May), 72(6): 587-91. doi:10.1002/pros.21465
- Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R. (2011) Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. PloS one (Jan), 6(11): e27178. doi:10.1371/journal.pone.0027178
Professional Memberships:
- Society of Basic Urologic Research (SBUR) (2022–present)
- Prostate Cancer Foundation (PCF) (2019–present)
- Cancer Epigenetic Society (CES) (2017–present)
- American Association for the Advancement of Science (2014–2019)
- American Society for Clinical Oncology (ASCO) (2012–present)
- American Association for Cancer Research (AACR) (2011–present)
Presentations:
- "Androgen Receptor as a Pro-Differentiation and Oncogenic Transcription Factor in Prostate Cancer," American Association for Cancer Research Annual Meeting 2024. San Diego Convention Center, American Association for Cancer Research Annual (2024)
- "Hormone-Refractory Prostate Cancer" 13th National Symposium on Prostate Cancer and Dr. Sidney A. McNairy, Jr. Student Symposium. Center for Cancer Research and Therapeutic Development at Clark Atlanta University (2023)
- "AR as a Pro-Differentiation and Oncogenic Transcription Factor" 2023 Coffey-Holden Prostate Cancer Foundation Academy, Prostate Cancer Foundation (2023)
- "Science Forward: Towards Inclusive Excellence in Academia" Associated Medical Schools of New York (AMSNY) Symposium, Cold Spring Harbor Laboratory (2023)
- "Effective Communication to Diverse Audiences" CTSI Scientific Communications Workshop Series, UB Clinical and Translational Science Institute- Workforce Development core (2022)
- "Alterations in AR regulome associated with systemic therapies for advanced prostate cancers" Cancer Research Consortium Seminar Series, University at Buffalo-Cancer Research Consortium (2021)
- "Epigenetic alterations associated with resistance to therapy: Focus in advanced renal cell carcinoma" Seminar, Department of Medicine, Imperial College, (2018)
Service Activities:
- NIH Study section, ATA; Grant Reviewer (2023–present)
- Health Disparities Research Peer Review panel of the FY23 Prostate Cancer Research Program for the Department of Defense Congressionally Directed Medical Research Programs; Grant Reviewer (2023)
- Cancer Research, American Association for Cancer Research Journal; ad hoc Manuscript Reviewer (2023–present)
- NIH Study section, MCTB,; Grant Reviewer (2023)
- Cancer Letters, Journal; ad hoc Manuscript Reviewer (2021–present)
- Frontiers in Oncology Journal; Review Editor (2021–present)
- Urology; ad hoc Manuscript Reviewer (2021)
- Molecular Cancer Therapeutics, American Association for Cancer Research Journal; ad hoc Manuscript Reviewer (2021)
- Young Investigator Award & Challenge Award Prostate Cancer Foundation; Grant Reviewer (2020–present)